News | October 31, 2025
BMS’ Cobenfy sees steady start, eyes stronger growth ahead
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Subscribe To Our Newsletter & Stay Updated
